Copyright: ©Author(s) 2026.
World J Virol. Mar 25, 2026; 15(1): 118274
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.118274
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.118274
Table 3 Comparison of comorbidities in survivors vs non-survivors, n (%)
| Variable | 2 months (n = 230) | 6 months (n = 198) | ||||
| Survivors | Non-survivors | SMD (95%CI) | Survivors | Non-survivors | SMD (95%CI) | |
| Diabetes mellitus | 44 (33.0) | 43 (45.0) | -0.25 (-0.51, 0.02) | 22 (30.0) | 54 (44.0) | -0.29 (-0.58, 0.00) |
| Hypertension | 85 (63.0) | 63 (66.0) | -0.05 (-0.31, 0.22) | 47 (64.0) | 79 (64.0) | 0.00 (-0.29, 0.28) |
| Coronary artery disease | 22 (16.0) | 21 (22.0) | -0.14 (-0.40, 0.12) | 11 (15.0) | 27 (22.0) | -0.18 (-0.47, 0.11) |
| Chronic kidney disease | 15 (11.0) | 11 (11.0) | -0.01 (-0.27, 0.25) | 6 (8.1) | 17 (14.0) | -0.18 (-0.47, 0.11) |
| Chronic obstructive pulmonary disease | 15 (11.0) | 19 (20.0) | -0.24 (-0.50, 0.02) | 8 (11.0) | 21 (17.0) | -0.18 (-0.47, 0.11) |
- Citation: Griner S, Elliott S, Giannis D, Quang CMPT, Inniss K, Miele A, Louis MA, Mandava NR. Evolution of tracheostomy practices after the COVID-19 pandemic: The fast lane in the post-COVID era. World J Virol 2026; 15(1): 118274
- URL: https://www.wjgnet.com/2220-3249/full/v15/i1/118274.htm
- DOI: https://dx.doi.org/10.5501/wjv.v15.i1.118274